BioSpace News Archive

Worldwide Clinical Trials, the industry’s leading global, midsize, full-service contract research organization, has announced the appointment of Barry Lederman as Chief Financial Officer to lead its finance, accounting, and legal functions.

9 Meters Biopharma, Inc., a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced that the Company will participate in Citi’s 17th Annual BioPharma Conference on September 8, 2022, in Boston.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will participate in a fireside chat at the Wells Fargo Healthcare Conference on Friday, September 9, 2022 at 11:00 a.m. ET.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced an expanded collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company, operating its biopharmaceuticals business in the U.S. and Canada as EMD Serono, to further leverage the GuardantINFORM real-world evidence (RWE) platform to help accelerate development efforts for Merck KGaA, Darmstadt, Germany‘s precision oncology pipeline.

Vaxart, Inc. announced that it has named Ray Stapleton, Ph.D., as its Chief Technology Officer, effective immediately.

Schrödinger, whose physics-based software platform is transforming the way therapeutics and materials are discovered, announced that management will participate at Citi’s 17th Annual BioPharma Conference.

Alimera Sciences, Inc. announces that clinical data for ILUVIEN® 0.19mg will be featured in more than 20 scientific abstracts during the EURETINA 2022 congress being held in Hamburg, Germany from September 1-4, 2022.

Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that the Company will present and host one-on-one meetings at the H.C. Wainwright 24th Annual Global Investment Conference in September.

Nanomix Corporation (OTCQB: NNMX) (“Nanomix” or the “Company”), a leader in the development of mobile, affordable, point-of-care diagnostics, today announced the appointment of Tadd S. Lazarus, M.D., to the Board of Directors as an independent director.

United BioPharma announced that the U.S. Food and Drug Administration has approved a phase 2 clinical trial IND submitted by the U.S. National Institute of Allergy and Infectious Diseases of NIH.